Compared with traditional exercise tests, cardiopulmonary exercise testing (CPET) provides a thorough assessment of exercise integrative physiology involving the pulmonary, cardiovascular, muscular, and cellular oxidative systems. Due to the prognostic ability of key variables, CPET applications in cardiology have grown impressively to include all forms of exercise intolerance, with a predominant focus on heart failure with reduced or with preserved ejection fraction. As impaired cardiac output and peripheral oxygen diffusion are the main determinants of the abnormal functional response in cardiac patients, invasive CPET has gained new popularity, especially for diagnosing early heart failure with preserved ejection fraction and exercise-induced pulmonary hypertension. The most impactful advance has recently come from the introduction of CPET combined with echocardiography or CPET imaging, which provides basic information regarding
I
n cardiopulmonary disorders, exercise intolerance is a major clinical feature from early stages, and becomes a source of symptoms and the reason for referral to a physician. Exercise limitation is one of the most disabling problems experienced by patients with heart failure (HF) (1) . Its quantification may be approximated by several methods, but a thorough analysis of the organ systems and pathways involved in the impaired physiological response is obtained by exercise gas exchange analysis with cardiopulmonary exercise testing (CPET). This technique enables the clinician to scrutinize reasons for dyspnea and fatigue to precisely differentiate cardiac from pulmonary disorders, optimize the decision-making process and outcome prediction, and objectively determine targets for therapies (2) .
Furthermore, CPET has become a reproducible (3) and safe technique (4) .
Despite this attractive evidence base and the clinical potential of CPET, the question put forth in the title of the present review (i.e., what is the value of CPET), is not trivial, and the definitive response requires mentioning a few historical notes and passages.
The idea of a CPET application in cardiology was introduced in the early 1980s by Weber et al. (5) , whose work allowed the landmark classification of patients with HF with reduced ejection fraction (HFrEF) based on peak oxygen consumption (VO 2 ), from A (peak VO 2 > 20 ml $ kg À1 $ min À1 ) to D (peak VO 2 < 10 ml $ kg À1 $ min À1 ) through B (peak VO 2 <20 to >15 ml $ kg À1 $ min À1 ) and C (peak VO 2 < 15 and 10 ml $ kg À1 $ min À1 ).
A few years later, Mancini et al. (6) , in their seminal 1991 paper, demonstrated that VO 2 measured at peak exercise stratifies the risk of cardiovascular (CV) death at 1 year in ambulatory patients with advanced HF.
These remarkable findings were subsequently validated and reproduced by several laboratories (7, 8) .
This solid evidence perhaps led to a quite paradoxical static vision of CPET applications for a long period (i.e., until the 2000s), with a single parametric approach focused just on advanced HF.
In the last 15 years, the utility of CPET has been increasingly recognized by both extending medical interest to the physiological bases of many variables that were previously under-recognized and by aligning evidence for a multivariable approach, including primarily abnormalities in ventilation and its control (1) . In HF, the combined use of variables has led to the generation of algorithms (9) and risk scores (10) (11) (12) covering the entire set of HF stages. This process has been witnessed and validated by a significant number of official documents and statements definitively (1,2,13) entering exercise gas exchange variables as study endpoint in the assessment of the effects of emerging pharmacological therapies (14,15) and in interventional trials (16, 17) . Along with the main developments in HF, the role of routine CPET in cardiology has been extended to specific patient populations, including those with suspected ischemic heart disease (18), congenital heart defects (19) , valve diseases (20) , hypertrophic cardiomyopathy (21) , suspected or confirmed pulmonary arterial hypertension (PAH) (22) , and left-sided pulmonary hypertension (PH) (23) .
In this paper, the modern key applications of CPET in CV diseases, with primary emphasis on HF, are discussed, starting from the principles that precipitate reduced exercise performance and impaired ventilation, and highlighting the most recent developments on combining exercise invasive hemodynamic and stress echocardiography with gas exchange evaluation. The large body of evidence on the established pathophysiological clinical and prognostic impact of CPET-derived variables will be emphasized, making a continuum of value from physiological bases to their translation into the practical applications. Accordingly, CPET is here proposed as a technique that may provide significant and synergistic advancements in the process of precision medicine and phenotyping.
GAS EXCHANGE ANALYSES AND THE PRINCIPAL BASES FOR EXERCISE LIMITATION IN HF
OXYGEN TRANSPORT AND USE. The body under physical stress behaves as a perfect machine that integrates and harmonizes the functional responses of multiple organs and pathways. In this process, the delivery of oxygen (O 2 ) to mitochondria is essential to perform at aerobic capacity (24 Guazzi et al. 
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Cardiopulmonary Exercise Testing pattern of increase (identifying the point of continuous increase in VE/VO 2 and stable VE/VCO 2 kinetics).
The lack of VO 2 at the first V T determination by any of these methods occurs in around 10% of patients with HF and carries a strong independent prognostic role (34) . Measuring gas exchange during submaximal exercise response to constant workload is the gold standard for studying the early VO 2 (A) In normal individuals, the increase in the VO 2 /WR relationship is 10 ml/kg/min irrespective of the ramp protocol. Physical deconditioning and initial cardiac limitation to exercise make this relationship shallow (B). Two patterns have been described in patients with advanced heart failure: VO 2 flattening (C) (i.e., loss of linearity from a certain point of exercise) and downsloping (D), which is tightly related to an acute drop in cardiac output and blood pressure. VO 2 ¼ peak oxygen consumption; WR ¼ work rate.
cardiogenic, rather than a peripheral vascular perfusion/extraction, limitation to exercise performance.
Finally, the addition of systolic blood pressure to the peak VO 2 , as circulatory power, has been proposed as having the potential to better investigate the circulatory impairment (36) .
VENTILATORY EFFICIENCY AND LUNG MECHANICS.
Cardiac patients may exhibit a lung mechanicalrelated mechanism of exercise limitation, which is tightly related to restrictive physiology due to congestion and physical interaction between the heart and the lung (37) . However, detection of lung mechanical dysfunction is often overlooked because patients with HF often display a normal breathing reserve, which is described by the relationship between exercise VE and maximal breathing capacity, 
APPLICATIONS OF CPET IN CLINICAL PRACTICE EVIDENCE IN PREVENTIVE MEDICINE AND REHABILITATION
PROGRAMS. Application of CPET to primary and secondary prevention is challenging. Interestingly, a role for CPET-derived data in detecting abnormal gas exchange pattern phenotypes has been just recently explored in the general population at CV risk.
An example is the European Exercise (EURO-EX)
population-based trial, whose preliminary data have highlighted some cases of EOV, typically occurring in the phenotype of elderly diabetic women (52) .
Overall, despite a wealth of persuasive evidence and numerous statements supporting the utility of
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CPET in prevention and in early HF stages, practitioners have not generally adopted a portfolio of variables that provides a 3-dimensional view of cardiorespiratory fitness with diagnostic and prognostic applicability, and an effective means to evaluate therapeutic benefits.
In the realm of patient care, exercise testing without the simultaneous collection of expired gases has seemingly taken on a static role, with the singular (but not exclusive) purpose of evaluating signs and symptoms of coronary insufficiency (53) . However, despite observations pointing out the high sensitivity and specificity of gas exchange analysis in detecting suspected myocardial ischemia (53, 54) , few of them recognize a CPET role.
Implementation of rehabilitation and exercise training (ET) programs is a Class I (55) to IIa (56) guideline recommendation. In this context, implementation EOV is a specific VE abnormal phenotype occurring in approximately 30% of patients with mid-to-late manifestations of chronic heart failure, characterized by cyclic fluctuation of VE and expired gas kinetics of variable amplitude, frequency, and duration. Because oscillatory manifestations may occur even in normal subjects, criteria for an abnormal definition are an oscillatory pattern at rest that persists for $60% of the exercise test at an amplitude of $15% of the average resting value (2). CPET ¼ cardiopulmonary exercise testing; EOV ¼ exercise oscillatory ventilation; HR ¼ heart rate; P ET CO 2 ¼ partial pressure of end-tidal carbon dioxide; P ET O 2 ¼ partial pressure of end-tidal oxygen; RR ¼ respiratory rate; VCO 2 ¼ volume of carbon dioxide released; VE ¼ ventilation; VO 2 ¼ peak oxygen
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of CPET is 3-fold: 1) to plan correct exercise intensity level or domain; 2) to assess benefits of exercise prescription by monitoring gas exchange variables and their related phenotypes; and 3) to identify subjects who, despite adherence to the program, are non-or poor responders to this multilevel intervention.
Although guidelines recommend the application of objective exercise prescriptions using CPET data (57), it is commonplace for programs without CPET capabilities or with limited resources to establish exercise intensity on the basis of resting heart rate (e.g., exercising heart rate threshold set 20 or 30 beats/min above the resting heart rate). This simple method has been criticized and demonstrated to be inadequate by many. For example, Reed et al. (58) reported that only 26% and 38% of participants were exercising at the recommended exercise intensity of 40% to 60% of heart rate reserve (confirmed by CPET) when using resting heart rate þ 20 and 30 beats/min, respectively. B All CPET variables in red: expected significantly diminished cardiac output, elevated neurohormones, higher potential for secondary PH. Greater number of CPET and standard ET variables in red/yellow/orange warrants strong consideration of more aggressive medical management and surgical options.
Example of a color-coded table for clinical stratification that applies to patients with either HFrEF or HFpEF. A list of evidence-based CPET variables (the VE/VCO2 slope, peak VO2, EOV, resting PETCO2) are separated into primary (e.g., the VE/VCO2 slope and peak VO2) and secondary (e.g., EOV and resting PETCO2) measures of interest, along with respective color-code categorizations of risk (2).
BP ¼ blood pressure; CPET ¼ cardiopulmonary exercise testing; ECG ¼ electrocardiogram; EOV ¼ exercise oscillatory ventilation; ET ¼ exercise testing; HF ¼ heart failure; HFrEF ¼ heart failure with reduced ejection fraction; HFpEF ¼ heart failure with preserved ejection fraction; HRR ¼ heart rate recovery; PETCO2 ¼ partial pressure of end-tidal carbon dioxide; PH ¼ pulmonary hypertension; VE/VCO2 ¼ minute ventilation/carbon dioxide production; VO2 ¼ oxygen consumption. 
Prognostic Recommendations
CPET should be performed in patients with HFrEF being considered for heart transplantation or mechanical device implantation. However, CPET provides robust prognostic information in all patients with HFrEF and therefore is also recommended in those not being considered for end-stage surgical management.
Class I A
Primary CPET variables, including the VE/VCO 2 slope, peak VO 2 , and EOV, are strong predictors of adverse events. The response of these 3 CPET variables is recommended to form the basis of the prognostic assessment in patients with HFrEF. A combination of a VE/VCO 2 slope $45.0, peak VO 2 #10 ml$kg À1 $min
À1
, and the presence of EOV carries a particularly poor prognosis.
Secondary CPET variables, including P ET CO 2 , O 2 pulse, systolic blood pressure, and the ECG response to exercise, are additional predictors of adverse events and can be useful during the prognostic assessment in patients with HFrEF. A resting P ET CO 2 <33 mm Hg, a rise in P ET CO 2 <3 mm Hg during exercise, a drop in systolic blood pressure during exercise, and/or ECG abnormalities warranting termination of exercise indicate a worse prognosis.
Class IIa B
Prognostic value in patients with HFpEF is showing initial promise, in particular, the VE/VCO 2 slope, peak VO 2 , and EOV. These variables can be useful in providing prognostic information also in patients with HFpEF.
Use of a multivariate model composed of key CPET variables and thresholds, as illustrated in Figure 4 , can be useful in improving prognostic resolution in patients with HFrEF in comparison with variables assessed independently.

Recommendations for Gauging Therapeutic Efficacy
Primary CPET variables, including the VE/VCO 2 slope and peak VO 2 , are responsive to numerous pharmacological, surgical, and exercise interventions in patients with HFrEF. As such, assessment of the change in the VE/VCO 2 slope and peak VO 2 is recommended when gauging therapeutic efficacy in patients with HFrEF in both clinical and research settings.
Class I A
Reversal of EOV also may occur with pharmacological and exercise interventions in patients with HFrEF. Therefore, assessing for reversal of EOV as a gauge of therapeutic efficacy can be useful in both clinical and research settings.
Class IIa B
Primary CPET variables, including the VE/VCO 2 slope and peak VO 2 , may be responsive to pharmacological, surgical, and exercise interventions in patients with HFpEF. As such, the VE/VCO 2 slope and peak VO 2 can be useful as core variables when gauging therapeutic efficacy in patients with HFpEF in both clinical and research settings.
Class IIa C
Diagnostic Recommendations
CPET variables reflecting ventilatory efficiency, including the VE/VCO 2 slope, EOV, and P ET CO 2 at rest and during exercise, may be considered in detecting left-sided PH in patients with HFrEF and HFpEF. If all 3 of these variables are in their respective red zones, as illustrated in Table 1 , the suspicion that the patient has left-sided PH may be reasonable. A primary indication of CPET for diagnostic purposes cannot be recommended at this time. Diagnostic assessments may be considered in patients with HF and suspicion of PH.
Class IIb B
Abbreviations as in Table 1 .
during exercise caused by breath, body motion, and heart movements. The intrinsic value of exercise echocardiography has been recently confirmed in an elegant
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